In contrast, mutations of transcription factor FOXP2 were shown in neoplastic plasma cells [83] and overexpression of FOXP2 is associated with high risk of early PSA recurrence in erythroblast transformation-specific-related gene (ERG) fusion-negative prostate cancers [84]. This evidence concerns the gene FOXP2 and prostate cancer.